CYP3A4

Function

CYP3A4 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of steroids (including cholesterol), and other lipids.

The CYP3A4 protein localizes to the endoplasmic reticulum, and its expression is induced by glucocorticoids and some pharmacological agents. Cytochrome P450 enzymes metabolize approximately 60% of prescribed drugs, with CYP3A4 responsible for about half of this metabolism; substrates include acetaminophen (paracetamol), codeine, ciclosporin (cyclosporin), diazepam, erythromycin, and chloroquine. The enzyme also metabolizes some steroids and carcinogens. Most drugs undergo deactivation by CYP3A4, either directly or by facilitated excretion from the body. Also, many substances are bioactivated by CYP3A4 to form their active compounds, and many protoxins are toxicated into their toxic forms (see table below for examples).

CYP3A4 also possesses epoxygenase activity in that it metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), i.e. (±)-8,9-, (±)-11,12-, and (±)-14,15-epoxyeicosatrienoic acids. EETs have a wide range of activities including the promotion of certain types of cancers (see epoxyeicosatetraenoic acid). CYP3A4 promotes the growth of various types of human cancer cell lines in culture by producing (±)-14,15-epoxyeicosatrienoic acids, which stimulate these cells to grow. The CYP3A4 enzyme is also reported to have fatty acid monooxgenase activity for metabolizing arachidonic acid to 20-Hydroxyeicosatetraenoic acid (20-HETE). 20-HETE has a wide range of activities that include growth stimulation in breast and other types of cancers (see 12-hydroxyeicosatetraenoic acid).

Evolution

The CYP3A4 gene exhibits a much more complicated upstream regulatory region in comparison with its paralogs. This increased complexity renders the CYP3A4 gene more sensitive to endogenous and exogenous pregnane X receptor (PXR) and constitutive androstane receptor (CAR) ligands, instead of relying on gene variants for wider specificity. Chimpanzee and human CYP3A4 are highly conserved in metabolism of many ligands, although four amino acids positively selected in humans led to a 5-fold benzylation of 7-BFC in the presence of the hepatotoxic secondary bile acid lithocholic acid. This change in consequence contributes to an increased human defense against cholestasis.

Tissue distribution

Fetuses do not express CYP3A4 in their liver tissue, but rather CYP3A7 (), which acts on a similar range of substrates. CYP3A4 increases to approximately 40% of adult levels in the fourth month of life and 72% at 12 months.

Although CYP3A4 is predominantly found in the liver, it is also present in other organs and tissues of the body, where it may play an important role in metabolism. CP3A4 is the major CYP enzyme in the intestine. CYP3A4 in the intestine plays an important role in the metabolism of certain drugs. Often this allows prodrugs to be activated and absorbed, as in the case of the histamine H1-receptor antagonist terfenadine.

CYP3A4 has also been identified in the brain, but its role in the central nervous system is unknown.

Mechanisms

Cytochrome P450 enzymes perform an assortment of modifications on a variety of ligands, utilizing its large active site and its ability to bind more than one substrate at a time to perform complicated chemical alterations in the metabolism of endogenous and exogenous compounds. These include hydroxylation, epoxidation of olefins, aromatic oxidation, heteroatom oxidations, N- and O- dealkylation reactions, aldehyde oxidations, dehydrogenation reactions, and aromatase activity.

Hydroxylation of an sp3 C-H bond is one of the ways in which CYP3A4 (and cytochrome P450 oxygenases) affects its ligand. In fact, hydroxylation is sometimes followed by dehydrogenation, leading to more complex metabolites. An example of a molecule that undergoes more than one reaction due to CYP3A4 includes tamoxifen, which is hydroxylated to 4-hydroxy-tamoxifen and then dehydrated to 4-hydroxy-tamoxifen quinone methide.

Two mechanisms have been proposed as the primary pathway of hydroxylation in P450 enzymes.

Inhibition through fruit ingestion

Main article: Grapefruit–drug interactions

In 1998, various researchers showed that grapefruit juice, and grapefruit in general, is a potent inhibitor of CYP3A4, which can affect the metabolism of a variety of drugs, increasing their bioavailability. In some cases, this can lead to a fatal interaction with drugs like astemizole or terfenadine. The effect of grapefruit juice with regard to drug absorption was originally discovered in 1989. The first published report on grapefruit drug interactions was in 1991 in the Lancet entitled "Interactions of Citrus Juices with Felodipine and Nifedipine", and was the first reported food-drug interaction clinically. The effects of grapefruit last from 3–7 days, with the greatest effects when juice is taken an hour previous to administration of the drug.

In addition to grapefruit, other fruits have similar effects. Noni (Morinda citrifolia), for example, is a dietary supplement typically consumed as a juice and also inhibits CYP3A4. Pomegranate juice has shown some inhibition in limited studies, but has not yet demonstrated the effect in humans.

Variability

While over 28 single nucleotide polymorphisms (SNPs) have been identified in the CYP3A4 gene, it has been found that this does not translate into significant interindividual variability in vivo. It can be supposed that this may be due to the induction of CYP3A4 on exposure to substrates.

CYP3A4 alleles that have been reported to have minimal function compared to wild-type include CYP3A46 (an A17776 insertion) and CYP3A417 (F189S). Both of these SNPs led to decreased catalytic activity with certain ligands, including testosterone and nifedipine in comparison to wild-type metabolism. By contrast, CYP3A41G* allele has more potent enzymatic activity compared to CYP3A41A* (the wild-type allele).

Variability in CYP3A4 function can be determined noninvasively by the erythromycin breath test (ERMBT). The ERMBT estimates in vivo CYP3A4 activity by measuring the radiolabelled carbon dioxide exhaled after an intravenous dose of (14C-N-methyl)-erythromycin.

Induction

CYP3A4 is induced by a wide variety of ligands. These ligands bind to the pregnane X receptor (PXR). The activated PXR complex forms a heterodimer with the retinoid X receptor (RXR), which binds to the XREM region of the CYP3A4 gene. XREM is a regulatory region of the CYP3A4 gene, and binding causes a cooperative interaction with proximal promoter regions of the gene, resulting in increased transcription and expression of CYP3A4. Activation of the PXR/RXR heterodimer initiates transcription of the CYP3A4 promoter region and gene. Ligand binding increases when in the presence of CYP3A4 ligands, such as in the presence of aflatoxin B1, M1, and G1. Indeed, due to the enzyme's large and malleable active site, it is possible for the enzyme to bind multiple ligands at once, leading to potentially detrimental side effects.

Induction of CYP3A4 has been shown to vary in humans depending on sex. Evidence shows an increased drug clearance by CYP3A4 in women, even when accounting for differences in body weight. A study by Wolbold et al. (2003) found that the median CYP3A4 levels measured from surgically removed liver samples of a random sample of women exceeded CYP3A4 levels in the livers of men by 129%. CYP3A4 mRNA transcripts were found in similar proportions, suggesting a pre-translational mechanism for the up-regulation of CYP3A4 in women. The exact cause of this elevated level of enzyme in women is still under speculation, however studies have elucidated other mechanisms (such as CYP3A5 or CYP3A7 compensation for lowered levels of CYP3A4) that affect drug clearance in both men and women.

CYP3A4 substrate activation varies amongst different animal species. Certain ligands activate human PXR, which promotes CYP3A4 transcription, while showing no activation in other species. For instance, mouse PXR is not activated by rifampicin and human PXR is not activated by pregnenolone 16α-carbonitrile In order to facilitate study of CYP3A4 functional pathways in vivo, mouse strains have been developed using transgenes in order to produce null/human CYP3A4 and PXR crosses. Although humanized hCYP3A4 mice successfully expressed the enzyme in their intestinal tract, low levels of hCYP3A4 were found in the liver. This effect has been attributed to CYP3A4 regulation by the growth hormone signal transduction pathway. In addition to providing an in vivo model, humanized CYP3A4 mice (hCYP3A4) have been used to further emphasize gender differences in CYP3A4 activity.

CYP3A4 activity levels have also been linked to diet and environmental factors, such as duration of exposure to xenobiotic substances. Due to the enzyme's extensive presence in the intestinal mucosa, the enzyme has shown sensitivity to starvation symptoms and is upregulated in defense of adverse effects. Indeed, in fatheaded minnows, unfed female fish were shown to have increased PXR and CYP3A4 expression, and displayed a more pronounced response to xenobiotic factors after exposure after several days of starvation. By studying animal models and keeping in mind the innate differences in CYP3A4 activation, investigators can better predict drug metabolism and side effects in human CYP3A4 pathways.

Turnover

Estimates of the turnover rate of human CYP3A4 vary widely. For hepatic CYP3A4, in vivo methods yield estimates of the enzyme half-life mainly in the range of 70 to 140 hours, whereas in vitro methods give estimates from 26 to 79 hours. Turnover of gut CYP3A4 is likely to be a function of the rate of enterocyte renewal; an indirect approach based on the recovery of activity following exposure to grapefruit juice yields measurements in the 12- to 33-hour range.

Technology

Due to membrane-bound CYP3A4's natural propensity to conglomerate, it has historically been difficult to study drug binding in both solution and on surfaces. Co-crystallization is difficult since the substrates tend to have a low KD (between 5–150 μM) and low solubility in aqueous solutions. A successful strategy in isolating the bound enzyme is the functional stabilization of monomeric CYP3A4 on silver nanoparticles produced from nanosphere lithography and analyzed via localized surface plasmon resonance spectroscopy (LSPR). These analyses can be used as a high-sensitivity assay of drug binding, and may become integral in further high-throughput assays utilized in initial drug discovery testing. In addition to LSPR, CYP3A4-Nanodisc complexes have been found helpful in other applications including solid-state NMR, redox potentiometry, and steady-state enzyme kinetics.

Ligands ==

Following are lists of selected substrates, inducers and inhibitors of CYP3A4. Where classes of agents are listed, there may be exceptions within the class.

Substrates

The substrates of CYP3A4 are:

• some immunosuppressants:
  • ciclosporin (cyclosporin),
  • tacrolimus,
  • sirolimus,
  • upadacitinib;
• many chemotherapeutics:
  • docetaxel,
  • tamoxifen,
  • paclitaxel,
  • cyclophosphamide,
  • doxorubicin,
  • erlotinib,
  • etoposide,
  • ifosfamide,
  • teniposide,
  • vinblastine,
  • vincristine,
  • vindesine,
  • imatinib,
  • irinotecan,
  • sorafenib,
  • sunitinib,
  • vemurafenib,
  • temsirolimus,
  • anastrozole,
  • gefitinib;
• azole antifungals:
  • ketoconazole
  • itraconazole
• macrolides (except azithromycin):
  • clarithromycin,
  • erythromycin,
  • telithromycin;
• dapsone (in leprosy),
• tricyclic antidepressants:
  • amitriptyline,
  • clomipramine,
  • imipramine,
  • cyclobenzaprine;
• SSRI antidepressants :
  • citalopram
  • norfluoxetine
  • sertraline
• some other antidepressants:
  • mirtazapine (NaSSA),
  • nefazodone (atypical),
  • reboxetine (NRI),
  • venlafaxine (SNRI),
  • trazodone (SARI),
  • vilazodone (serotonin modulator),
• buspirone (anxiolytic),
• antipsychotics:
  • haloperidol,
  • aripiprazole,
  • risperidone,
  • ziprasidone,
  • pimozide,
  • quetiapine,
  • lurasidone;
• opioids (mainly analgesics):
  • alfentanil,
  • buprenorphine (analgesic, addiction maintenance treatment),
  • codeine (analgesic, antitussive, antidiarrheal),
  • fentanyl,
  • hydrocodone (partial involvement, not the bioactivation factor),
  • methadone (analgesic, addiction maintenance treatment),
  • levacetylmethadol,
  • tramadol (analgesic, refractory RLS treatment);
• benzodiazepines:
  • alprazolam,
  • midazolam,
  • triazolam,
  • diazepam, (bioactivation to desmethyldiazepam)
  • clonazepam;
• some hypnotics:
  • zopiclone,
  • zaleplon,
  • zolpidem,
• donepezil (acetylcholinesterase inhibitor),
• statins (except pravastatin and rosuvastatin):
  • atorvastatin,
  • lovastatin,
  • simvastatin,
  • cerivastatin;
• calcium channel blockers:
  • diltiazem),
  • felodipine),
  • nifedipine),
  • verapamil),
  • amlodipine),
  • lercanidipine,
  • nitrendipine,
  • nisoldipine,
• amiodarone (class III antiarrhythmic),
• dronedarone (class III antiarrhythmic),
• quinidine (class I antiarrhythmic),
• PDE5 inhibitors:
  • sildenafil,
  • tadalafil,
• kinins (vasodilators, smooth muscle contractors),
• steroids:
  • sex hormones (agonists and antagonists):
    • finasteride (antiandrogen),
    • estradiol (estrogen),
    • progesterone,
    • ethinylestradiol (hormonal contraceptive),
    • testosterone (androgen),
    • toremifene (SERM),
    • bicalutamide;
  • glucocorticoids:
    • budesonide,
    • hydrocortisone (cortisol),
    • dexamethasone,
    • fluticasone;
• some H1-receptor antagonists (H1 antihistamines):
  • ketotifen,
  • terfenadine,
  • astemizole,
  • chlorphenamine;
• protease inhibitors:
  • indinavir,
  • ritonavir,
  • saquinavir,
  • nelfinavir;
• non-nucleoside reverse-transcriptase inhibitors (antiretroviral drugs):
  • nevirapine
  • delavirdine,
  • efavirenz,
  • etravirine,
  • rilpivirine;
• albendazole (antihelminthic)
• cisapride, (5-HT4 receptor agonist)
• aprepitant, (antiemetic)
• caffeine, (stimulant)
• cocaine, (stimulant)
• cilostazol, (phosphodiesterase inhibitor)
• dextromethorphan, (antitussive)
• domperidone, (antidopaminergic)
• eplerenone, (aldosterone antagonist)
• lidocaine, (local anesthetic, antiarrhythmic)
• ondansetron, (5-HT3 antagonist)
• propranolol, (beta blocker)
• salmeterol, (beta agonist)
• warfarin, (anticoagulant)
• clopidogrel becoming bioactivated (antiplatelet),
• 2-oxo-clopidogrel,
• omeprazole, (proton pump inhibitor)
• nateglinide, (antidiabetic)
• methoxetamine,
• montelukast (leukotriene receptor antagonist),
• vilaprisan (selective progesterone receptor modulator),
• certain angiotensin II receptor blockers:
  • losartan (sensitive substrates)
  • irbesartan.

Inhibitors

Inhibitors of CYP3A4 are classified by potency:

• a Strong inhibitor causes at least a 5-fold increase in the plasma AUC values, or more than 80% decrease in clearance.
• a Moderate inhibitor causes at least a 2-fold increase in the plasma AUC values, or 50–80% decrease in clearance.
• a Weak inhibitor causes at least a 1.25-fold but less than 2-fold increase in the plasma AUC values, or 20–50% decrease in clearance.

The inhibitors of CYP3A4 are the following substances.

Strong inhibitors

• boceprevir,
• protease inhibitors:
  • ritonavir,
  • indinavir,
  • nelfinavir,
  • saquinavir;
• some macrolide antibiotics:
  • clarithromycin,
  • erythromycin (although FDA lists it as a moderate inhibitor, and inhibitor of P-glycoprotein, defined as those increasing the AUC of digoxin to ≥1.25-fold);
  • telithromycin
• ceritinib
• mibefradil (used for the treatment of hypertension and chronic angina pectoris)
• nefazodone (antidepressant)
• ribociclib
• tucatinib
• chloramphenicol (antibiotic)
• some azole antifungals:
  • ketoconazole,
  • itraconazole,
  • posaconazole,
  • voriconazole;
• cobicistat,
• green tea extract,
• grape seed extract,
• dillapiole (compound present in dill plants),
• apigenin (compound present in plants such as celery, parsley, and chamomile)
• Artemisia annua

Moderate inhibitors

• amiodarone (class III antiarrhythmic),
• aprepitant, (antiemetic)
• ciprofloxacin,
• conivaptan,
• crizotinib,
• rutin (in vitro) (dietary flavonoid),
• tofisopam,
• some calcium channel blockers:
  • verapamil,
  • diltiazem;
• some azole antifungals:
  • fluconazole,
  • miconazole;
• bergamottin (constituent of grapefruit juice),
• cyclosporine,
• donedarone,
• fluvoxamine,
• imatinib,
• valerian.

Weak inhibitors

• berberine (an alkaloid found in plants such as berberis or goldenseal),
• buprenorphine (analgesic),
• cafestol (in unfiltered coffee)
• cilostazol,
• cimetidine,
• fosaprepitant,
• lomitapide,
• orphenadrine,
• omeprazole (proton pump inhibitor),
• quercetin,
• ranitidine,
• ranolazine,
• tacrolimus,
• ticagrelor,
• valproic acid,
• amlodipine,
• azithromycin (macrolide antibiotic).

Inhibitors of unspecified potency

• bergaptol (a furocoumarin in citrus),
• cannabidiol,
• dithiocarbamate (functional group),
• flavonoids,
• mifepristone (abortifacient),
• norfloxacin (fluoroquinolone antibiotic),
• some non-nucleoside reverse-transcriptase inhibitors:
  • delavirdine;
• gestodene (hormonal contraceptive),
• star fruit,
• milk thistle,
• niacin (nicotinic acid) and its form – niacinamide (nicotinamide), collectively called as Vitamin B3,
• ginkgo biloba,
• sesamin (a lignan constituent in sesame seeds and oil),
• piperine,
• isoniazid,
• serenoa,
• phenelzine.

Inducers

Strong and moderate CYP3A4 inducers are drugs that decrease the AUC of sensitive substrates of a given pathway where CYP3A4 is involved by ≥80 percent and ≥50 to

The inducers of CYP3A4 are the following substances.

Strong inducers

• carbamazepine,
• antiandrogens:
  • enzalutamide,
  • apalutamide;
• primidone
• phenytoin (anticonvulsant),
• rifampin.

Weak inducers

• upadacitinib.

Inducers of unspecified potency

• anticonvulsants, mood stabilizers:
  • oxcarbazepine,
  • topiramate;
• barbiturates:
  • phenobarbital,
  • butalbital:
• St. John's wort,
• some bactericidals:
  • rifampicin,
  • rifabutin;
• some non-nucleoside reverse-transcriptase inhibitors:
  • efavirenz,
  • nevirapine;
• troglitazone (hypoglycemic),
• glucocorticoids (blood glucose increase, immunosuppressive),
• modafinil (stimulant),
• capsaicin,
• brigatinib,
• clobazam,
• dabrafenib,
• elagolix,
• eslicarbazepine,
• letermovir,
• lorlatinib,
• oritavancin,
• perampanel,
• telotristat.

Interactive pathway map

References

References

1. (December 1993). "Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control". European Journal of Biochemistry.
2. (June 1992). "Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization". The Japanese Journal of Human Genetics.
3. "CYP3A4 cytochrome P450 family 3 subfamily A member 4 [ Homo sapiens (human) ]".
4. (April 2013). "Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation". Pharmacology & Therapeutics.
5. {{EntrezGene. 1576
6. (2014). "Lipid-metabolizing CYPs in the regulation and dysregulation of metabolism". Annual Review of Nutrition.
7. (October 2014). "The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease". Pharmacological Reviews.
8. (June 2001). "HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme". British Journal of Pharmacology.
9. (March 2010). "The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability". Pharmacogenetics and Genomics.
10. (June 2009). "Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection". Drug Metabolism and Disposition.
11. (2006). "Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children". Clinical Pharmacokinetics.
12. (May 2008). "Development of CYP2D6 and CYP3A4 in the first year of life". Clinical Pharmacology and Therapeutics.
13. (2010). "Grapefruit-drug interactions". [[Drugs (journal).
14. (July 2003). "Transgenic mouse models of human CYP3A4 gene regulation". Molecular Pharmacology.
15. (November 1997). "Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins". Drug Metabolism and Disposition.
16. (October 2012). "Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen". Biochimica et Biophysica Acta (BBA) - General Subjects.
17. (September 2004). "Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes". Chemical Reviews.
18. (April 1998). "Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice". Chemical Research in Toxicology.
19. (August 1998). "Grapefruit juice-drug interactions". British Journal of Clinical Pharmacology.
20. (September 1998). "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy". Clinical Pharmacology and Therapeutics.
21. (2004). "Interactions between grapefruit juice and cardiovascular drugs". American Journal of Cardiovascular Drugs.
22. (November 2006). "Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs". Geriatrics.
23. (October 2000). "Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin". Clinical Pharmacology and Therapeutics.
24. "Integrative Medicine, Noni". Memorial Sloan-Kettering Cancer Center.
25. (May 2005). "Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats". Drug Metabolism and Disposition.
26. (2020). "Pomegranate Juice does not Affect the Bioavailability of Cyclosporine in Healthy Thai Volunteers". Curr Clin Pharmacol.
27. (June 2005). "Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests". Pharmacogenomics.
28. Alkattan A, Alsalameen E. Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment. Expert Opin Drug Metab Toxicol. 2021 Apr 30. doi: 10.1080/17425255.2021.1925249. Epub ahead of print. PMID 33931001.
29. (August 1994). "Noninvasive tests of CYP3A enzymes". Pharmacogenetics.
30. (August 2011). "Aflatoxins upregulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor". Toxicology Letters.
31. (October 2003). "Sex is a major determinant of CYP3A4 expression in human liver". Hepatology.
32. (2007). "CYP3A4 and pregnane X receptor humanized mice". Journal of Biochemical and Molecular Toxicology.
33. (September 2011). "Influence of gender, feeding regimen, and exposure duration on gene expression associated with xenobiotic metabolism in fathead minnows ({{lang". Comparative Biochemistry and Physiology. Toxicology & Pharmacology.
34. (June 2008). "Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions". Current Drug Metabolism.
35. (January 2012). "Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand". The Journal of Biological Chemistry.
36. (May 2009). "Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy". Analytical Chemistry.
37. link. (11 June 2002 Facts for prescribers (Fakta för förskrivare). Retrieved July 2011)
38. "[https://www.ema.europa.eu/en/documents/assessment-report/rinvoq-epar-public-assessment-report_en.pdf Rinvoq: EPAR – Public assessment report] {{Webarchive. link. (21 July 2020 " (PDF). [[European Medicines Agency]]. 5 March 2020. Archived (PDF) from the original on 21 July 2020. Retrieved 21 July 2020.)
39. ''Austria-Codex'' (in German). Vienna: Österreichischer Apothekerverlag. 2020. Rinvoq 15 mg Retardtabletten.
40. "Erlotinib".
41. "Cyclobenzaprine". DrugBank.
42. (2022). "StatPearls". StatPearls Publishing.
43. (December 2009). "Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes". Drug Metabolism and Disposition.
44. (Mar 2004). "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes". British Journal of Clinical Pharmacology.
45. (October 1999). "Clinically significant pharmacokinetic drug interactions with benzodiazepines". Journal of Clinical Pharmacy and Therapeutics.
46. (May 1997). "Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression". American Society for Clinical Investigation.
47. (July 1996). "Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice". Springer Nature.
48. (June 1991). "Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4". Journal of Medicinal Chemistry.
49. (June 2010). "Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation". American Society for Pharmacology & Experimental Therapeutics (ASPET).
50. (April 2005). "Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms". Journal of Clinical Pharmacy and Therapeutics.
51. (29 November 2012). "NIFEDIPINE EXTENDED RELEASE- nifedipine tablet, extended release".
52. (1992). "The effect of three different oral doses of verapamil on the disposition of theophylline". European Journal of Clinical Pharmacology.
53. (February 1990). "Verapamil-induced inhibition of theophylline elimination in healthy humans". Pharmacology & Toxicology.
54. (August 1989). "The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers". Journal of Clinical Pharmacology.
55. (July 1988). "Effect of calcium channel blockers on theophylline disposition". Clinical Pharmacology and Therapeutics.
56. (March 1988). "Selective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects on theophylline". British Journal of Clinical Pharmacology.
57. (March 1988). "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans". The Journal of Pharmacology and Experimental Therapeutics.
58. "Active ingredient: Tadalafil - Brands, Medical Use, Clinical Data". Druglib.com.
59. (2004). "Bicalutamide: clinical pharmacokinetics and metabolism". Clinical Pharmacokinetics.
60. (August 2019). "Iatrogenic Cushing's syndrome with inhaled fluticasone". Australian Prescriber.
61. (2015). "Analysis for commonly prescribed non-sedating antihistamines". Analytical Chemistry Research.
62. (2006). "H1 antihistamines: psychomotor performance and driving". J Investig Allergol Clin Immunol.
63. (July 2022). "Pharmacogenomics for the efficacy and side effects of antihistamines". Exp Dermatol.
64. (November 2001). "Standard treatment: the role of antihistamines". J Investig Dermatol Symp Proc.
65. (February 2001). "Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine". British Journal of Clinical Pharmacology.
66. (2016-01-01). "Chapter 6 - Therapeutic Drug Monitoring of Antiretrovirals". Elsevier.
67. Enzyme [http://www.genome.jp/dbget-bin/www_bget?enzyme+1.14.13.32 1.14.13.32] {{Webarchive. link. (27 March 2017 at [[KEGG]])
68. "Showing Protein Cytochrome P450 3A4 (HMDBP01018)".
69. (May 2003). "Pharmacogenetics of oral anticoagulants". Pharmacogenetics.
70. (January 2003). "Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction". Circulation.
71. (July 2013). "Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn". Analytical and Bioanalytical Chemistry.
72. (26 December 2018). "LOSARTAN- losartan potassium tablet, film coated".
73. (May 2000). "In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists". Eur J Clin Pharmacol.
74. (2007). "Drug Interactions: Cytochrome P₄₅₀ Drug Interaction Table". [[Indiana University School of Medicine]].
75. (6 May 2023). "Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". US Food and Drug Administration.
76. (August 2021). "Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin". AAPS J.
77. (July 2002). "Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol". Clin Pharmacol Ther.
78. (December 2023). "Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs: Recommendations for Clinical Practice". Dtsch Ärztebl Int.
79. (April 2020). "Interaction potential between clarithromycin and individual statins-A systematic review". Basic Clin Pharmacol Toxicol.
80. (November 2003). "Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes". Antimicrobial Agents and Chemotherapy.
81. Center for Drug Evaluation and Research. "Drug Interactions & Labeling - Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers".
82. (November 2020). "The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats". BMC Pharmacology & Toxicology.
83. (August 2004). "Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam". Drug Metabolism and Pharmacokinetics.
84. (2009). "Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4". Drug Metabolism and Drug Interactions.
85. (June 2019). "Potent CYP3A4 Inhibitors Derived from Dillapiol and Sesamol". ACS Omega.
86. (December 2018). "Food Bioactive Compounds and Their Interference in Drug Pharmacokinetic/Pharmacodynamic Profiles". Pharmaceutics.
87. (May 2021). "Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids". Molecules.
88. (January 2023). "''Artemisia annua'' L. Extracts Irreversibly Inhibit the Activity of CYP2B6 and CYP3A4 Enzymes". Biomedicines.
89. (December 2016). "Modulatory effects of rutin on the expression of cytochrome P450s and antioxidant enzymes in human hepatoma cells". Acta Pharmaceutica.
90. (2017). "Inhibition of Cytochrome P450 (CYP3A4) Activity by Extracts from 57 Plants Used in Traditional Chinese Medicine (TCM)". Pharmacognosy Magazine.
91. Product Information: ORAVIG(R) buccal tablets, miconazole buccal tablets. Praelia Pharmaceuticals, Inc (per FDA), Cary, NC, 2013.
92. (2021). "Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling and promoting G0/G1 cell cycle block and apoptosis". PLOS ONE.
93. "Valerian: Health Benefits, Side Effects, Uses, Dose & Precautions".
94. (2021). "The Intracellular Mechanism of Berberine-Induced Inhibition of CYP3A4 Activity". Curr Pharm Des.
95. (December 2023). "An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations". J Pharmacol Exp Ther.
96. (September 2012). "Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions". Planta Medica.
97. (September 2018). "The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins". Chemico-Biological Interactions.
98. (June 2003). "Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro". Drug Metabolism and Disposition.
99. (2009). "Interaction of coffee diterpenes, cafestol and kahweol, with human P-glycoprotein". The American Association of Pharmaceutical Scientists.
100. (December 2021). "Determination of effective concentrations of drug absorption enhancers using in vitro and ex vivo models". Eur J Pharm Sci.
101. (2001). "In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)". Br J Clin Pharmacol.
102. (February 2024). "Bergaptol, a Major Furocoumarin in Citrus: Pharmacological Properties and Toxicity". Molecules.
103. (April 2011). "Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety". Life Sciences.
104. (March 2024). "Flavonoids as CYP3A4 Inhibitors In Vitro". Biomedicines.
105. Non-nucleoside reverse-transcriptase inhibitors have been shown to both induce and inhibit CYP3A4.
106. (June 2004). "Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity". Drug Metabolism and Disposition.
107. "HCVadvocate.org".
108. (May 2004). "Inhibition of human P450 enzymes by nicotinic acid and nicotinamide". Biochemical and Biophysical Research Communications.
109. (January 2010). "Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity". Food and Chemical Toxicology.
110. (2012). "Sesamin: A Naturally Occurring Lignan Inhibits CYP3A4 by Antagonizing the Pregnane X Receptor Activation". Evidence-Based Complementary and Alternative Medicine.
111. (August 2002). "Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4". The Journal of Pharmacology and Experimental Therapeutics.
112. (January 2002). "Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes". European Journal of Clinical Pharmacology.
113. (May 2010). "Natural Products in Epilepsy-the Present Situation and Perspectives for the Future". Pharmaceuticals.
114. Gillman, Peter Kenneth. (February 2011). "Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors". Journal of Clinical Psychopharmacology.
115. (2021). "A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs". Front Pharmacol.
116. (November 2015). "Rang & Dale's pharmacology". Churchill Livingstone.
117. Astellas Pharma US, Inc.. (August 2012). "Highlights of Prescribing Information: XTANDI (enzalutamide) capsules for oral use". U.S. Food and Drug Administration.
118. (Feb 2015). "AExposure to CYP3A4 inducing and CYP3A4 non-inducing antiepileptic agents and the risk of fractures". Pharmacoepidemiol Drug Saf.
119. (September 2010). "Antiepileptic drug interactions - principles and clinical implications". Current Neuropharmacology.
120. (December 2003). "Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate". Epilepsia.
121. (May 2012). "Capsaicin induces CYP3A4 expression via pregnane X receptor and CCAAT/enhancer-binding protein β activation". Molecular Nutrition & Food Research.